These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 12242728

  • 1. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
    Bruckheimer EM, Kyprianou N.
    Prostate; 2002 Oct 01; 53(2):133-42. PubMed ID: 12242728
    [Abstract] [Full Text] [Related]

  • 2. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y, Kyprianou N.
    Cancer Res; 1999 Mar 15; 59(6):1366-71. PubMed ID: 10096572
    [Abstract] [Full Text] [Related]

  • 3. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 4. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
    Angelucci C, Iacopino F, Lama G, Capucci S, Zelano G, Boca M, Pistilli A, Sica G.
    Anticancer Res; 2004 Feb 15; 24(5A):2729-38. PubMed ID: 15517879
    [Abstract] [Full Text] [Related]

  • 5. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
    Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ.
    J Urol; 2003 Apr 15; 169(4):1553-7. PubMed ID: 12629413
    [Abstract] [Full Text] [Related]

  • 6. The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
    Kim IY, Zelner DJ, Lee C.
    Exp Cell Res; 1998 May 25; 241(1):151-60. PubMed ID: 9633523
    [Abstract] [Full Text] [Related]

  • 7. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone.
    Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C.
    Exp Cell Res; 1996 Jan 10; 222(1):103-10. PubMed ID: 8549651
    [Abstract] [Full Text] [Related]

  • 8. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells.
    Bruckheimer EM, Kyprianou N.
    Endocrinology; 2001 Jun 10; 142(6):2419-26. PubMed ID: 11356690
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R.
    Cancer Res; 1995 Oct 01; 55(19):4438-45. PubMed ID: 7671257
    [Abstract] [Full Text] [Related]

  • 10. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C.
    Cancer Res; 2003 Nov 01; 63(21):7106-12. PubMed ID: 14612503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation.
    Winter RN, Rhee JG, Kyprianou N.
    Anticancer Res; 2004 Nov 01; 24(3a):1377-86. PubMed ID: 15274298
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.
    Tobin SW, Brown MK, Douville K, Payne DC, Eastman A, Arrick BA.
    Cell Growth Differ; 2001 Feb 01; 12(2):109-17. PubMed ID: 11243465
    [Abstract] [Full Text] [Related]

  • 14. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
    Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP.
    Cancer Res; 1995 Feb 15; 55(4):735-8. PubMed ID: 7850782
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
    Evangelou A, Jindal SK, Brown TJ, Letarte M.
    Cancer Res; 2000 Feb 15; 60(4):929-35. PubMed ID: 10706107
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
    Lee SO, Lou W, Johnson CS, Trump DL, Gao AC.
    Prostate; 2004 Aug 01; 60(3):178-86. PubMed ID: 15176047
    [Abstract] [Full Text] [Related]

  • 17. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP.
    Clin Cancer Res; 2002 Dec 01; 8(12):3922-32. PubMed ID: 12473608
    [Abstract] [Full Text] [Related]

  • 18. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
    Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK.
    Prostate Cancer Prostatic Dis; 2002 Dec 01; 5(3):236-45. PubMed ID: 12496988
    [Abstract] [Full Text] [Related]

  • 19. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ.
    BJU Int; 2006 Jan 01; 97(1):170-8. PubMed ID: 16336351
    [Abstract] [Full Text] [Related]

  • 20. Selective loss of the transforming growth factor-beta apoptotic signaling pathway in mutant NRP-154 rat prostatic epithelial cells.
    Larisch-Bloch S, Danielpour D, Roche NS, Lotan R, Hsing AY, Kerner H, Hajouj T, Lechleider RJ, Roberts AB.
    Cell Growth Differ; 2000 Jan 01; 11(1):1-10. PubMed ID: 10672898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.